Scarica l'app Stockscreener
14.03
1.06%
-0.15
Dopo l'orario di chiusura:
13.88
-0.15
-1.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$14.18
Aprire:
$14.34
Volume 24 ore:
1.15M
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.57B
Reddito:
$577.74M
Utile/perdita netta:
$-149.78M
Rapporto P/E:
-10.02
EPS:
-1.4
Flusso di cassa netto:
$-78.21M
1 W Prestazione:
-2.09%
1M Prestazione:
+10.65%
6M Prestazione:
-11.37%
1 anno Prestazione:
-21.49%
Intervallo 1D:
$13.93
$14.62
Intervallo di 1 settimana:
$12.84
$14.62
Portata 52W:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Confronta NVCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.03 | 1.47B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
127.63 | 231.95B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
97.78 | 142.60B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.25 | 141.45B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.04 | 123.83B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.65 | 43.07B | 5.69B | 1.41B | 577.90M | 6.9828 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
Why NovoCure Limited stock is rated strong buyAnalyst Downgrade & Daily Price Action Insights - newser.com
NovoCure Limited stock volume spike explainedWeekly Stock Recap & Weekly Return Optimization Alerts - newser.com
Novocure to present tumor treating fields data at upcoming oncology congresses - Investing.com Australia
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress - Yahoo Finance
Tumor Treating Fields Market Demand, Growth, and Future Scope (2025-2032) Featuring Novocure GmbH and Zai Lab - openPR.com
How to manage a losing position in NovoCure LimitedStop Loss & Momentum Based Trading Signals - newser.com
Is NovoCure Limited stock ready for a breakoutWeekly Trend Report & High Conviction Buy Zone Picks - newser.com
What sentiment indicators say about NovoCure Limited stockTrade Risk Assessment & Daily Volume Surge Signals - newser.com
Should you wait for a breakout in NovoCure LimitedPortfolio Performance Summary & Stepwise Trade Execution Plans - newser.com
NovoCure (NVCR): Evaluating Valuation as METIS Phase 3 Brain Metastases Results Reach Industry Conference Milestone - simplywall.st
Using data tools to time your NovoCure Limited exitJuly 2025 Trends & Target Return Focused Stock Picks - newser.com
NovoCure's (NVCR) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Final METIS Trial Results for TTFields Therapy Could Be a Game Changer for NovoCure (NVCR) - Sahm
Should I buy NovoCure Limited (038) stock before earnings seasonJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why NovoCure Limited (038) stock remains top ratedEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com
NovoCure Ltd. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
NovoCure (NASDAQ:NVCR) vs. Evogene (NASDAQ:EVGN) Head-To-Head Analysis - Defense World
NovoCure Limited (NVCR) Stock Analysis: A Closer Look at an 87.5% Potential Upside in the Medical Device Sector - DirectorsTalk Interviews
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of “Hold” by Analysts - Defense World
Published on: 2025-10-05 04:02:03 - newser.com
Analyzing NovoCure Limited with multi timeframe chartsQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
NovoCure (NVCR): Assessing Valuation After Positive Phase 3 METIS Trial Results Unveiled - simplywall.st
Volume spikes in NovoCure Limited stock – what they mean2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will NovoCure Limited (038) stock keep high P E multiplesRecession Risk & Safe Entry Trade Signal Reports - newser.com
Why NovoCure (NVCR) Is Up 9.9% After Phase 3 METIS Trial Success in Brain Metastases - simplywall.st
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Medical Technology Firm Novocure Schedules Q3 2025 Financial Results with Investor Conference Call - Stock Titan
Novocure to Report Third Quarter 2025 Financial Results - The Globe and Mail
Why NovoCure Limited is moving todayQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data - Investing.com Nigeria
NovoCure's (NVCR) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Pattern recognition hints at NovoCure Limited upsideTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com
Novocure (NVCR) Announces Positive Phase 3 METIS Trial Results - GuruFocus
Novocure’s cancer therapy delays brain metastases progression By Investing.com - Investing.com Australia
Novocure’s cancer therapy delays brain metastases progression - Investing.com India
15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial - Stock Titan
Live market analysis of NovoCure LimitedJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
Washington Capital Management Inc. Invests $374,000 in NovoCure Limited $NVCR - MarketBeat
How NovoCure Limited stock benefits from strong dollarJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Regression analysis insights on NovoCure Limited performancePortfolio Risk Report & Fast Gain Swing Alerts - newser.com
Published on: 2025-09-28 23:33:37 - newser.com
NovoCure Limited stock outlook for YEARJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
Is NovoCure Limited (038) stock a buy on weaknessJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
42,600 Shares in NovoCure Limited $NVCR Purchased by Strs Ohio - MarketBeat
How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer - simplywall.st
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novocure Ltd Azioni (NVCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
1.23%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):